مورد إلكتروني
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
| العنوان: | The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. |
|---|---|
| بيانات النشر: | American Society of Hematology (E-mail: publishing@hematology.org) United States 2019-04-22 |
| تفاصيل مُضافة: | Forsyth C. Tatarczuch M. Burbury K. Motorna O. Shortt J. Ratnasingam S. Chan K.-L. Hsu W.-H. Ashraf A. Putt F. Grigg A. Minson A.G. Cummins K. Fox L. Costello B. Yeung D. Cleary R. Fleming S. McQuillan A. Schwarer A. Harrup R. Holmes A. |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses in chronic myeloid leukemia in chronic phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding the best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk of vascular AEs (VAEs) compared with other TKIs, although the natural history of these events in response to dose modifications or cessation has not been fully characterized. We retrospectively reviewed the incidence of nilotinib-associated AEs in 220 patients with CML-CP at 17 Australian institutions. Overall, AEs of any grade were reported in 95 patients (43%) and prompted nilotinib cessation in 46 (21%). VAEs occurred in 26 patients (12%), with an incidence of 4.1 events per 100 patient-years. Multivariate analysis identified age (P 5 .022) and dyslipidemia (P 5 .007) as independent variables for their development. There was 1 fatal first VAE, whereas the remaining patients either continued nilotinib (14 patients) or stopped it immediately (11 patients). Recurrent VAEs were associated with ongoing therapy in 7 of 14 who continued (with 2 fatal VAEs) vs 1 of 11 who discontinued (P 5 .04). Nineteen of the 23 evaluable patients surviving a VAE ultimately stopped nilotinib, of whom 14 received an alternative TKI. Dose reduction or cessation because of VAEs did not adversely affect maintenance of major molecular response. These findings demonstrate that in contrast to other AEs, VAEs are ideally managed with nilotinib cessation because of the increased risk of additional events with its ongoing use.Copyright © 2019 by The American Society of Hematology. |
| مصطلحات الفهرس: | psoriasis/si [Side Effect], rash/si [Side Effect], retrospective study, treatment response, vascular disease/si [Side Effect], nilotinib/ae [Adverse Drug Reaction], nilotinib/do [Drug Dose], nilotinib/dt [Drug Therapy], prednisolone/dt [Drug Therapy], groups by age, acute coronary syndrome/si [Side Effect], adult, aged, article, cerebrovascular disease/si [Side Effect], chronic myeloid leukemia/dt [Drug Therapy], cohort analysis, diarrhea/si [Side Effect], drug withdrawal, dyslipidemia, erythema/si [Side Effect], erythema nodosum/si [Side Effect], fatigue/si [Side Effect], female, folliculitis/si [Side Effect], hepatitis/si [Side Effect], history, human, incidence, lethargy/si [Side Effect], major clinical study, male, myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], otitis media/si [Side Effect], pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], peripheral vascular disease/si [Side Effect], pleura effusion/dt [Drug Therapy], pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, Article |
| URL: | LibKey Link |
| الإتاحة: | Open access content. Open access content Copyright 2019 Elsevier B.V., All rights reserved. |
| أرقام أخرى: | AUSHL oai:repository.monashhealth.org:1/35604 Blood Advances. 3 (7) (pp 1084-1091), 2019. Date of Publication: 09 Apr 2019. 2473-9529 https://repository.monashhealth.org/monashhealthjspui/handle/1/35604 30944100 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30944100] 2001816210 (Minson, Cummins, Fox, Putt, Grigg) Department of Clinical Haematology, Austin Hospital, Melbourne, Australia (Fox, Tatarczuch, Burbury) Peter MacCallum Cancer Centre, Melbourne, Australia (Costello) Baker IDI Heart and Diabetes Institute, Melbourne, Australia (Yeung) Royal Adelaide Hospital, Adelaide, Australia (Cleary) Princess Alexandra Hospital, Brisbane, Australia (Forsyth) Gosford Hospital, Gosford, Australia (Motorna, Shortt) Monash Health, Melbourne, Australia (Shortt) School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia (Fleming) Alfred Hospital, Melbourne, Australia (McQuillan) Hollywood Medical Centre, Perth, Australia (Schwarer) Box Hill Hospital, Melbourne, Australia (Harrup) Royal Hobart Hospital, Hobart, Australia (Holmes) Canberra Hospital, Canberra, Australia (Ratnasingam) Royal Melbourne Hospital, Melbourne, Australia (Chan) St Vincent's Hospital, Melbourne, Australia (Hsu) Royal Prince Alfred Hospital, Sydney, Australia (Ashraf) Calvary Mater Hospital, Newcastle, Australia Minson A.G.; agminson@gmail.com 1305107461 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1305107461 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |